CD3 News and Research

RSS

Beckman Coulter Life Sciences launches industry-first infrared dye antibody conjugates to expand human phenotyping experiments

Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, announces the launch of its new IR820 and IR870 infrared dye antibody conjugates.

From Beckman Coulter Life Sciences - Flow Cytometry 15 Sep 2025

UCLA team develops engineered antibodies to fight cytomegalovirus infection

A UCLA research team has found a new way to prompt the immune system to kill cells infected with cytomegalovirus (CMV), a life-threatening infection that is particularly deadly in immunocompromised people.

13 Sep 2025

A universal solution emerges: Anti-linker antibodies simplify CAR-T detection and development

CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid tumors.

From Sino Biological Inc. 13 Sep 2025

Novel insights from lymphoid structures: Lessons from colorectal cancer research

Discover how lymphoid structures and germinal centers provide powerful prognostic insights into colorectal cancer.

From TissueGnostics 31 Jul 2025

New monoclonal antibody enhances immune response by selectively targeting Tregs

A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment."

17 Jul 2025

Innovative bispecific antibody targets LAG-3 to treat autoimmune diseases

Immune checkpoint pathways regulate T cell function and play pivotal roles in the treatment of both cancer and autoimmune diseases.

7 Jul 2025

Study provides a molecular snapshot of Tanshi constitution's immunological landscape

The study aims to uncover the immunological basis of Tanshi (phlegm-dampness) constitution—a subhealth type in traditional Chinese medicine (TCM)—using single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs).

7 Jul 2025

Engineered protein silences harmful T cells in autoimmune disease

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of Type-1 diabetes, hepatitis, multiple sclerosis, shows a new study in mice.

1 Jul 2025

Nasal spray may offer new hope for traumatic brain injury patients

A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI).

27 Feb 2025

New immune therapy improves survival and reduces tumor burden in glioblastoma

The Wistar Institute's David B. Weiner, Ph.D. - Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research - and his lab have successfully tested a new immune therapy that, in preclinical lab testing, reliably improves survival and reduces tumor burden in glioblastoma.

3 Dec 2024

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR T-cells. This breakthrough enhances tumor targeting while reducing off-target effects, paving the way for advanced synthetic biology applications.

17 Nov 2024

New CAR T cells offer controlled treatment for solid tumors

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells - a type of cancer immunotherapy - that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs.

21 Oct 2024

Frailty linked to diminished quality of life in cancer and transplant survivors

A new research paper was published on the in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 18 on September 26, 2024, entitled, "Frailty and pre-frailty associated with long-term diminished physical performance and quality of life in breast cancer and hematopoietic cell transplant survivors."

2 Oct 2024